|
[1]
|
Chaudhari, P.B., Pathy, S., Deo, S.S.V., Chawla, B. and Mridha, A.R. (2017) Alveolar Soft Part Sarcoma of Orbit: A Rare Diagnosis. Journal of the Egyptian National Cancer Institute, 29, 167-170. [Google Scholar] [CrossRef] [PubMed]
|
|
[2]
|
Paoluzzi, L. and Maki, R.G. (2019) Diagnosis, Prognosis, and Treatment of Alveolar Soft-Part Sarcoma: A Review. JAMA Oncology, 5, 254-260. [Google Scholar] [CrossRef] [PubMed]
|
|
[3]
|
Meng, N., Zhang, X., Liao, A., Tian, S., Ran, W., Gao, Y. and Wang, J.J. (2014) Management of Recurrent Alveolar Soft-Part Sarcoma of the Tongue after External Beam Radiothera-py with Iodine-125 Seed Brachytherapy. Head & Neck, 36, E125-E128. [Google Scholar] [CrossRef] [PubMed]
|
|
[4]
|
Kummar, S., et al. (2013) Cediranib for Metastatic Alveolar Soft Part Sar-coma. Journal of Clinical Oncology, 31, 2296-2302. [Google Scholar] [CrossRef]
|
|
[5]
|
Boulay, G., et al. (2017) Cancer-Specific Retargeting of BAF Complexes by a Prion-Like Domain. Cell, 171, 163-178. [Google Scholar] [CrossRef] [PubMed]
|
|
[6]
|
Reichardt, P., Lindner, T., Pink, D., Thuss-Patience, P.C., Kretzschmar, A. and Dörken, B. (2003) Chemotherapy in Alveolar Soft Part Sarcomas. What Do We Know? European Journal of Cancer, 39, 1511-1516. [Google Scholar] [CrossRef]
|
|
[7]
|
Flores, R.J., Harrison, D.J., Federman, N.C., Furman, W.L., Huh, W.W., Broaddus, E.G., Okcu, M.F. and Venkatramani, R. (2018) Alveolar Soft Part Sarcoma in Children and Young Adults: A Report of 69 Cases. Pediatric Blood & Cancer, 65, e26953. [Google Scholar] [CrossRef] [PubMed]
|
|
[8]
|
Arakawa, S., Asano, Y., Kawabe, N., Nagata, H., Kondo, Y., Furuta, S., Shimura, M., Hayashi, C., Ochi, T., Kamio, K., Kawai, T., Yasuoka, H., Higashiguchi, T., Ishihara, S., Ito, M., Imaeda, Y. and Horiguchi, A. (2020) Resection of Pancreatic and Splenic Metastases from Alveolar Soft Part Sarcoma: A Case Report. Surgical Case Reports, 6, Article No. 139. [Google Scholar] [CrossRef] [PubMed]
|
|
[9]
|
Chang, X., Li, Y., Xue, X., Zhou, H. and Hou, L. (2021) The Current Management of Alveolar Soft Part Sarcomas. Medicine (Bal-timore), 100, e26805. [Google Scholar] [CrossRef]
|
|
[10]
|
Hei, Y., Kang, L., Yang, X., et al. (2018) Orbital Alveolar Soft Part Sarcoma: A Report of 8 Cases and Review of the Literature. Oncology Letters, 15, 304-314. [Google Scholar] [CrossRef] [PubMed]
|
|
[11]
|
Chi, Y., Yang, Y., et al. (2018) Anlotinib for Metastasis Soft Tissue Sarcoma: A Randomized, Double-Controlled and Multi-Centered Clinical Trial. Journal of Clinical Oncology, 36, 11503. [Google Scholar] [CrossRef]
|
|
[12]
|
Stacchiotti, S., Mir, O., Le Cesne, A., et al. (2018) Ac-tivity of Pazopanib and Trabectedin in Advanced Alveolar Soft Part Sarcoma. Oncologist, 23, 62-70. [Google Scholar] [CrossRef] [PubMed]
|
|
[13]
|
Schöffski, P., Wozniak, A., Kasper, B., Aamdal, S., Leahy, M.G., Rutkowski, P., Bauer, S., Gelderblom, H., Italiano, A., Lindner, L.H., Hennig, I., Strauss, S., Zakotnik, B., An-thoney, A., Albiges, L., Blay, J.Y., Reichardt, P., Sufliarsky, J., van der Graaf, W.T.A., Debiec-Rychter, M., Sciot, R., Van Cann, T., Marréaud, S., Raveloarivahy, T., Collette, S. and Stacchiotti, S. (2018) Activity and Safety of Crizotinib in Patients with Alveolar Soft Part Sarcoma with Rearrangement of TFE3: European Organization for Research and Treat-ment of Cancer (EORTC) Phase II Trial 90101 ‘CREATE’. Annals of Oncology, 29, 758-765. [Google Scholar] [CrossRef] [PubMed]
|
|
[14]
|
Saerens, M., Brusselaers, N., Rottey, S., Decruyenaere, A., Creytens, D. and Lapeire, L. (2021) Immune Checkpoint Inhibitors in Treatment of Soft-Tissue Sarcoma: A Systematic Review and Meta-Analysis. European Journal of Cancer, 152, 165-182. [Google Scholar] [CrossRef] [PubMed]
|
|
[15]
|
Zhu, M.M.T., Shenasa, E. and Nielsen, T.O. (2020) Sarcomas: Immune Biomarker Expression and Checkpoint Inhibitor Trials. Cancer Treatment Reviews, 91, Article ID: 102115. [Google Scholar] [CrossRef] [PubMed]
|
|
[16]
|
Hindi, N., Razak, A., Rosenbaum, E., Jonczak, E., Hamacher, R., Rutkowski, P., Bhadri, V.A., Skryd, A., Brahmi, M., Alshibany, A., Jagodzinska-Mucha, P., Bauer, S., Connolly, E., Gelderblom, H., Boye, K., Henon, C., Bae, S., Bogefors, K., Vin-cenzi, B., Martinez-Trufero, J., Lopez-Martin, J.A., Redondo, A., Valverde, C., Blay, J.Y., Moura, D.S., Gutierrez, A., Tap, W. and Martin-Broto, J. (2023) Efficacy of Immune Checkpoint Inhibitors in Alveolar Soft-Part Sarcoma: Results from a Retrospective Worldwide Registry. ESMO Open, 8, Article ID: 102045. [Google Scholar] [CrossRef] [PubMed]
|
|
[17]
|
Somaiah, N., Conley, A.P., Parra, E.R., Lin, H., Amini, B., Solis Soto, L., Salazar, R., Barreto, C., Chen, H., Gite, S., Haymaker, C., Nassif, E.F., Bernatchez, C., Mitra, A., Living-ston, J.A., Ravi, V., Araujo, D.M., Benjamin, R., Patel, S., Zarzour, M.A., Sabir, S., Lazar, A.J., Wang, W.L., Daw, N.C., Zhou, X., Roland, C.L., Cooper, Z.A., Rodriguez-Canales, J., Futreal, A., Soria, J.C., Wistuba, I.I. and Hwu, P. (2022) Durvalumab plus Tremelimumab in Advanced or Metastatic Soft Tissue and Bone Sarcomas: A Single-Centre Phase 2 Trial. The Lancet Oncology, 23, 1156-1166. [Google Scholar] [CrossRef]
|
|
[18]
|
Bergsma, E.J., Elgawly, M., Mancuso, D., Orr, R., Vusko-vich, T. and Seligson, N.D. (2023) Atezolizumab as the First Systemic Therapy Approved for Alveolar Soft Part Sar-coma. Annals of Pharmacotherapy, 10600280231187421. [Google Scholar] [CrossRef] [PubMed]
|
|
[19]
|
O’Sullivan Coyne, G., Naqash, A.R., Sankaran, H. and Chen, A.P. (2021) Advances in the Management of Alveolar Soft Part Sarcoma. Current Problems in Cancer, 45, Article ID: 100775. [Google Scholar] [CrossRef] [PubMed]
|